| Name | Title | Contact Details |
|---|
Worldwide Clinical Research is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Novasite Pharmaceutical is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The vision of AlliancePharma Inc. is to offer a service that is human, professional and personalized, and fosters the development of the skills of the replacement pharmacists and pharmacy technicians. In the long term, AlliancePharma Inc. strives to increase and improve the value of its privileged position in the area of pharmacy replacement services, as well as diversifying its activities in high value added sectors linked to health.
Headquartered in Denmark, Novo Nordisk has more than 5,000 employees in the United States – representing 16% of the total workforce. From our insulin product manufacturing facility in Clayton, , North Carolina, to our Research and Development Center in Seattle, Washington we bring value to communities across the country in a variety of ways. Our newly constructed LEED-certified building in Plainsboro, New Jersey, is modeled on principles of functionality, innovation, openness, quality, and aesthetics-offering a space that promotes collaboration and creativity.
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).